The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products. The guidance would replace 2018 guidance to include recommendations for labeling interchangeable products, among other changes. The agency has approved 42 biosimilar products, including four interchangeable biosimilars. 
 

Related News Articles

Headline
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and…
Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…